Wall Street expects a year-over-year increase in earnings on higher revenues when Globus Medical (GMED) reports results for the quarter ended December 2024. While this widely-known consensus outlook ...

State of Alaska Department of Revenue reduced its stake in shares of Globus Medical, Inc. (NYSE:GMED – Free Report) by 1.2% ...

Engaged Capital exited its stakes in BlackLine (NASDAQ:BL) and Nevro (NYSE:NVRO) and took a new position in Chart Industries (NYSE:GTLS) in Q4 2024, among other moves.  The hedge fund, known for its ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Globus Medical (GMED – Research Report) and ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Globus Medical, Inc.’s GMED growth in the third quarter can be attributed to the robust prospect in the musculoskeletal space. The company’s merger with NuVasive is expected to generate ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

The company currently has its sales operations distributed across 51 counties worldwide. GMED is a Zacks Rank #3 (Hold) stock, with a Growth Style Score of A and VGM Score of A. Earnings are ...

Stock analysts at Roth Capital dropped their FY2024 earnings per share (EPS) estimates for shares of Globus Medical in a research note issued on Monday, January 27th. Roth Capital analyst J. Wittes ...